Related Experiment Video

Updated: Aug 1, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians

K Lottermoser1, R Düsing, P Ervens

  • 1Medizinische Universitäts-Poliklinik, Bonn, Germany.

Journal of Molecular Medicine (Berlin, Germany)
|August 4, 2001
PubMed

Insights

The plasminogen activator inhibitor 1 (PAI-1) 4G/5G genotype did not significantly impact longevity in individuals over 80. This study found no strong evidence linking PAI-1 genotype to overall mortality in this elderly cohort.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Longevity Research
  • Molecular Biology

Background:

  • Plasma levels of plasminogen activator inhibitor 1 (PAI-1) are implicated in coronary artery disease risk.
  • PAI-1 regulation involves both environmental and genetic factors.
  • The PAI-1 4G/5G gene polymorphism, particularly the 4G allele, is associated with increased PAI-1 expression and potential cardiovascular risk.

Purpose of the Study:

  • To investigate the association between the PAI-1 4G/5G genotype and longevity.
  • To determine if the PAI-1 genotype influences survival in individuals aged 80 and older.

Main Methods:

  • Retrospective cohort study involving 205 subjects aged 80+.
  • Analysis of the PAI-1 4G/5G polymorphism using a light-cycler assisted method.
  • Genotyping for 4G/4G, 4G/5G, and 5G/5G variants.

Main Results:

  • The allele distribution in the cohort (4G/5G: 47%, 4G/4G: 30%, 5G/5G: 23%) was comparable to general population data.
  • No significant association was observed between the PAI-1 genotype and longevity in this elderly group.
  • The observed allele frequencies did not differ markedly from those in larger cohorts not selected for age.

Conclusions:

  • The PAI-1 4G/5G genotype does not appear to be a major determinant of total mortality in individuals aged 80 and older.
  • The study suggests that the PAI-1 genotype may have a limited role in influencing lifespan in the very elderly.
  • Further research in larger, diverse cohorts may be warranted to fully elucidate the role of PAI-1 in aging and mortality.

More Related Videos

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Concept Videos

Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...